Sotac Pharmaceuticals Ltd
Incorporated in 2015, Co. is in the business of manufacturing pharmaceutical products for different marketers on a loan license or contract manufacturing basis[1]
- Market Cap ₹ 137 Cr.
- Current Price ₹ 124
- High / Low ₹ 155 / 97.0
- Stock P/E 23.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 29.7 %
- ROE 32.0 %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|
43.44 | 73.15 | 57.98 | 63.97 | |
40.58 | 65.13 | 49.73 | 53.72 | |
Operating Profit | 2.86 | 8.02 | 8.25 | 10.25 |
OPM % | 6.58% | 10.96% | 14.23% | 16.02% |
0.35 | -1.63 | 0.24 | 0.69 | |
Interest | 0.61 | 0.58 | 0.90 | 1.07 |
Depreciation | 1.11 | 1.13 | 1.63 | 2.22 |
Profit before tax | 1.49 | 4.68 | 5.96 | 7.65 |
Tax % | 0.00% | 29.91% | 24.66% | |
1.48 | 3.30 | 4.50 | 5.60 | |
EPS in Rs | 6.43 | 14.35 | 5.59 | 5.49 |
Dividend Payout % | 0.00% | 13.94% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -21% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -2% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 8% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 32% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|
Equity Capital | 2.30 | 2.30 | 8.05 | 11.05 |
Reserves | 2.51 | 4.80 | 12.94 | 34.36 |
6.68 | 7.39 | 10.66 | 11.38 | |
11.01 | 21.82 | 23.13 | 14.72 | |
Total Liabilities | 22.50 | 36.31 | 54.78 | 71.51 |
6.42 | 8.80 | 14.09 | 18.08 | |
CWIP | 0.00 | 0.00 | 0.04 | 0.05 |
Investments | 0.00 | 0.00 | 4.00 | 9.10 |
16.08 | 27.51 | 36.65 | 44.28 | |
Total Assets | 22.50 | 36.31 | 54.78 | 71.51 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
2.22 | 3.58 | 8.54 | |
-1.07 | -3.28 | -10.93 | |
-1.17 | -0.30 | 11.97 | |
Net Cash Flow | -0.02 | 0.00 | 9.57 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
Debtor Days | 52.68 | 62.57 | 72.40 |
Inventory Days | 40.71 | 35.14 | 87.26 |
Days Payable | 112.49 | 128.97 | 165.78 |
Cash Conversion Cycle | -19.10 | -31.25 | -6.12 |
Working Capital Days | 26.97 | 29.09 | 24.93 |
ROCE % | 54.66% | 29.74% |
Business Verticals
A) Manufacturing of Non-Beta-Lactam Medicines and Formulations [1]
It manufactures Non-Beta-Lactam (general) tablets, Non-Beta-Lactam (general) capsules, oral liquid, dry syrup, and external preparations such as Ointment, Lotion, and cream and caters to 162 corporate clients on a loan license and/or contract manufacturing basis